Researchers Study Link Between Exercise and Recovery Time in Stem Cell Transplantation
News Feb 01, 2013
High-dose chemotherapy followed by marrow or stem cell transplantation can cure blood-borne cancers like lymphoma and leukemia but poses a high risk of severe complications or even death during the first 100 days post-treatment, says Eileen Danaher Hacker, UIC associate professor of biobehavioral health science and lead researcher of the study.
Severe fatigue often accompanies chemotherapy, which can lead patients to decrease their physical activity, Hacker said. She developed an exercise program called Strength Training to Enhance Early Recovery, or STEER, that uses elastic resistance bands to increase muscle mass and functional ability and improve patients’ quality of life.
She will recruit about 75 patients being treated by stem cell or marrow transplantation at the University of Illinois Hospital & Health Sciences System for the new study. They will either use the STEER program or participate in a health education program while continuing with their usual rest, activity and exercise.
Patients will exercise three times a week — once supervised by health care professionals in a clinical setting, and twice at home, Hacker said. They will be assessed three times during the study for amount of physical activity, fatigue, muscle strength, functional ability, quality of life, and frailty.
Strength training, in comparison to other exercises, is most effective at building muscle mass, Hacker said, but few studies have focused on patients undergoing high-dose chemotherapy.
“Muscle strength is needed for physical activity and for a body to function properly,” she said. “Without it, frailty and long-term disability may occur, even though the transplant survivors are cancer-free.
“Strength training is possible during the early recovery period if it is tailored to the individual’s capabilities.”
Phenogenetic Map Created For Stem Cell Models Of Neurological DiseasesNews
Researchers at The Ohio State University Wexner Medical Center have performed the first meta-analysis of all induced pluripotent stem cell models for neurological and neurodegenerative diseases, and created an atlas of how cell characteristics are linked to their genotype.READ MORE
Gilead Company Wins FDA Approval for CAR T Cancer Therapy for Treatment of Adult LymphomaNews
Kite’s Yescarta™ (axicabtagene ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.READ MORE
Overexpression of a Cell-cycle Activator Gene Enhances Repair of Dead Heart MuscleNews
Biomedical engineers report a significant advance in efforts to repair a damaged heart after a heart attack, using grafted heart-muscle cells to create a repair patch.READ MORE